These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Chistiakov DA; Chekhonin VP Eur J Pharmacol; 2012 Jun; 684(1-3):8-18. PubMed ID: 22484336 [TBL] [Abstract][Full Text] [Related]
4. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Garzon R; Marcucci G Curr Opin Oncol; 2012 Nov; 24(6):655-9. PubMed ID: 23079782 [TBL] [Abstract][Full Text] [Related]
5. Targeting miRNAs in osteoblast differentiation and bone formation. Hu R; Li H; Liu W; Yang L; Tan YF; Luo XH Expert Opin Ther Targets; 2010 Oct; 14(10):1109-20. PubMed ID: 20690886 [TBL] [Abstract][Full Text] [Related]
6. [Molecular targets for prevention of age-related diseases]. Niida S Nihon Rinsho; 2012 Nov; 70 Suppl 8():383-7. PubMed ID: 23513870 [No Abstract] [Full Text] [Related]
7. MicroRNAs as therapeutic targets for lung cancer. Cho WC Expert Opin Ther Targets; 2010 Oct; 14(10):1005-8. PubMed ID: 20854177 [TBL] [Abstract][Full Text] [Related]
8. Direct detection of small RNAs using splinted ligation. Maroney PA; Chamnongpol S; Souret F; Nilsen TW Nat Protoc; 2008; 3(2):279-87. PubMed ID: 18274530 [TBL] [Abstract][Full Text] [Related]
9. LNA-FISH for detection of microRNAs in frozen sections. Silahtaroglu AN Methods Mol Biol; 2010; 659():165-71. PubMed ID: 20809310 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. Nana-Sinkam SP; Croce CM IDrugs; 2010 Dec; 13(12):843-6. PubMed ID: 21154140 [TBL] [Abstract][Full Text] [Related]
11. Exploiting microRNAs for cell engineering and therapy. Bratkovič T; Glavan G; Strukelj B; Zivin M; Rogelj B Biotechnol Adv; 2012; 30(3):753-65. PubMed ID: 22286072 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of microRNAs in cancer. Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365 [TBL] [Abstract][Full Text] [Related]
13. miRNA-101: a potential target for tumor therapy. Gui T; Shen K Cancer Epidemiol; 2012 Dec; 36(6):537-40. PubMed ID: 22647681 [TBL] [Abstract][Full Text] [Related]
14. Antagomirzymes: oligonucleotide enzymes that specifically silence microRNA function. Jadhav VM; Scaria V; Maiti S Angew Chem Int Ed Engl; 2009; 48(14):2557-60. PubMed ID: 19229913 [TBL] [Abstract][Full Text] [Related]
15. New developments of the various classes of oligonucleotides. Preface. Eckstein F Ann N Y Acad Sci; 2009 Sep; 1175():1-2. PubMed ID: 19796071 [No Abstract] [Full Text] [Related]
16. Electrotransfer of RNAi-based oligonucleotides for oncology. Chabot S; Pelofy S; Paganin-Gioanni A; Teissie J; Golzio M Anticancer Res; 2011 Dec; 31(12):4083-9. PubMed ID: 22199265 [TBL] [Abstract][Full Text] [Related]
17. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Han J; Lee Y; Yeom KH; Nam JW; Heo I; Rhee JK; Sohn SY; Cho Y; Zhang BT; Kim VN Cell; 2006 Jun; 125(5):887-901. PubMed ID: 16751099 [TBL] [Abstract][Full Text] [Related]
18. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Lee JW; Park YA; Choi JJ; Lee YY; Kim CJ; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS Gynecol Oncol; 2011 Jan; 120(1):56-62. PubMed ID: 21035172 [TBL] [Abstract][Full Text] [Related]
19. Short-RNA selective binding of oligonucleotides modified using adenosine and guanosine derivatives that possess cyclohexyl phosphates as substituents. Seio K; Kurohagi S; Kodama E; Masaki Y; Tsunoda H; Ohkubo A; Sekine M Org Biomol Chem; 2012 Feb; 10(5):994-1006. PubMed ID: 22143376 [TBL] [Abstract][Full Text] [Related]
20. Silencing of microRNAs in vivo with 'antagomirs'. Krützfeldt J; Rajewsky N; Braich R; Rajeev KG; Tuschl T; Manoharan M; Stoffel M Nature; 2005 Dec; 438(7068):685-9. PubMed ID: 16258535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]